2024 : 12 : 27

Raheleh Majdani

Academic rank: Assistant Professor
ORCID:
Education: PhD.
ScopusId:
HIndex:
Faculty: 1
Address:
Phone:

Research

Title
Phage therapy: a new therapeutic solution for infected wounds
Type
Presentation
Keywords
bacteriophages, multidrug-resistant bacteria, wound infection
Year
2022
Researchers Raheleh Majdani

Abstract

Background and Aim : Wound infections have been explained as severe conditions especially in hospitals. In addition to extensive tissue damage and nonhealing wounds, septicemia can increase the mortality rate of wound infections. The most important causative agents of wound infections are included: Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Because of high prevalence of antibiotic resistant bacteria and limitations to discovery of new effective antibiotics, finding new approaches to combat bacterial infections has been inevitable recently. Methods : In this study, we reviewed the results of using bacteriophages against wounds MDR (Multi-drug resistant) bacterial infections focusing on experimental assays, animal models and clinical trials. Phages effectiveness in wound healings was surveyed based on previous reports. Results : According to the results, phages have high potential to prevent wound infections by MDR bacteria, faster healing of the infections and removing bacterial biofilms with lower toxicity than antibiotics. Animal models were used to determine the phages activity against the infections. Using combinational therapy (phage-antibiotic) and phage cocktails were reported as more efficient methods to control the infections and also reducing the antibiotic resistances. In addition, using new delivery systems could be very helpful in wounds phage therapy. Conclusion : In spite of successful experiments of phage therapy indicating high potential of bacteriophages to prevent and remove wound infections, more studies are needed to extensive therapeutic uses of bacteriophages and manufacturing the regularly therapeutic phage-based products.